Antisense Therapeutics (ASX:ANP) receives first approval for phase two DMD clinical trial
Antisense Therapeutics (ASX:ANP) has received approval to conduct its phase two trial in non-ambulant boys with DMD in Turkey.
Source: themarketherald.com.au
Thomas Voit News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Thomas Voit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Thomas Voit Today - Breaking & Trending Today
Researchers combine motion capture and AI to treat movement disorders
UK researchers have shown that AI can be combined with motion capture suits to create a "faster, cheaper" way of treating movement disorders.
Source: dezeen.com
Using motion capture technology and AI to monitor the progression of movement disorders
A multi-disciplinary team of researchers has developed a way to monitor the progression of movement disorders using motion capture technology and AI.
Source: news-medical.net
Wearable Tech and AI Combine to Track Progression of Movement Disorders
Combining new wearable technology and artificial intelligence, researchers are better able to track motion and monitor the progression of movement disorders.
Source: neurosciencenews.com
World-class health research at UCL awarded £145M
UCL is the research partner of the NIHR UCLH BRC, awarded £90m, the NIHR Great Ormond Street Hospital (GOSH) BRC, awarded £35m, and the NIHR Moorfields BRC, awarded £20m. The total award to UCL is the most of any UK university and signals the strength of UCL’s world-class translational research and scientific discovery.
Source: sciencebusiness.net